Tarsons Products Limited (NSE: TARSONS, BSE: 543399) is a Kolkata, West Bengal-based company in the Life Sciences Tools and Services industry. With a market capitalisation of ₹1,730 Cr, it ranks #1,306 by market cap among the 6,197 Indian listed companies on FinBizNet, and #4 of 10 in Life Sciences Tools and Services. At ₹304.30 (as of 19 Nov 2026), the share price is 18.9% below its 52-week high of ₹375.00 and 85.0% above its 52-week low of ₹164.45. The share price is up 25.7% over one year and down 11.7% over three months.
| Current Price | ₹304.30 |
|---|---|
| Market Cap | ₹1,730 Cr |
| NSE Symbol | TARSONS |
| BSE Code | 543399 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | 114.9 |
| Return on Equity | 2.26% |
| Return on Assets | 0.94% |
| 52-Week Range | ₹164.45 – ₹375.00 |
| 1-Year Price Change | +25.7% |
| 3-Month Price Change | -11.7% |
| Beta (1Y) | 0.6 |
| Dividend Yield | 0.00% |
| Headquarters | Kolkata, West Bengal |
| Website | www.tarsons.com |
| Revenue | ₹124 Cr |
|---|---|
| Net Profit | ₹-0 Cr |
| Net Margin | -0.3% |
| EPS (Basic) | ₹-0.06 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Tarsons Products Limited reported revenue of ₹124 Cr in Q2 FY27, up 20.8% from ₹102 Cr in Q2 FY26 and up 12.2% from ₹110 Cr in Q1 FY27. It posted a net loss of ₹0 Cr for the quarter, against a net profit of ₹3 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹91 Cr (Q1 FY26) to ₹124 Cr (Q2 FY27). The company reported a net loss in 2 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹124 Cr | −₹0 Cr | −0.3% |
| Q1 FY27 | ₹110 Cr | −₹1 Cr | −1.3% |
| Q4 FY26 | ₹121 Cr | ₹4 Cr | 3.5% |
| Q3 FY26 | ₹108 Cr | ₹5 Cr | 4.7% |
| Q2 FY26 | ₹102 Cr | ₹3 Cr | 3.2% |
| Q1 FY26 | ₹91 Cr | ₹2 Cr | 1.9% |
| Q4 FY25 | ₹113 Cr | ₹10 Cr | 9.1% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 47.30% of Tarsons Products Limited's shares as of Sept 2026, against 47.31% in Sept 2025 (−0.01 percentage points). Delivery averaged 52.3% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).
Tarsons Products Limited manufactures and trades in scientific plastic labware products in India and internationally. The company offers bottles and carboys; boxes and racks; cell cell culture ware, centrifuge ware, clamps and stands, cryoware, desiccator, tubings and connectors, filtration, genomics and PCR consumables, laboratory equipment and utilities, liquid handling consumables and reusables, magnetic stirrer bar, pp storage plates, sampling aids, vials and tubes, and volumetric reusables. It also provides general lab ware products. Its products are used in molecular biology, cell culture, genomics, proteomics, and immunology. Tarsons Products Limited was incorporated in 1983 and is headquartered in Kolkata, India.
1. Manufacturing and Selling of Plastic Laboratory Products and Certain Scientific Instruments-This segment manufactures and sells plastic laboratory products and various scientific instruments.
1. Plastic Laboratory Products and Certain Scientific Instruments-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Indegene Ltd | ₹14,840 Cr | 40.2 | 13.94% | ₹1,122 Cr | +26.1% |
| Suven Life Sciences Ltd. | ₹7,951 Cr | n/m | -78.80% | ₹1 Cr | +51.8% |
| Vimta Labs Ltd | ₹2,259 Cr | 29.5 | 18.55% | ₹112 Cr | -26.8% |
| Tarsons Products Limited | ₹1,730 Cr | 114.9 | 2.26% | ₹124 Cr | +25.7% |
| Brooks Laboratories Ltd. | ₹198 Cr | 7.9 | 22.28% | ₹19 Cr | -34.2% |
| Bilcare Ltd. | ₹194 Cr | 108.3 | -5.21% | — | — |
| Jeevan Scientific Technology Ltd | ₹176 Cr | 129.4 | 1.68% | — | +42.3% |
| Vivo Bio Tech Ltd. | ₹37 Cr | n/m | -2.00% | ₹14 Cr | -55.7% |
| Dr. Habeebbullal Life Sciences Ltd | ₹26 Cr | n/m | -68.79% | — | -45.3% |
Listed by market capitalisation. Ratios are shown for context only.
Tarsons Products Limited is trading at ₹304.30, with a market capitalisation of ₹1,730 Cr.
Tarsons Products Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Tarsons Products Limited has a P/E of 114.9 and a return on equity of 2.26%.
Tarsons Products Limited is listed on the NSE under the symbol TARSONS and on the BSE under the scrip code 543399.
Tarsons Products Limited's share price is up 25.7% over one year and down 11.7% over three months. Its 52-week range is ₹164.45 to ₹375.00.
In Q2 FY27, Tarsons Products Limited reported revenue of ₹124 Cr and net profit of ₹-0 Cr, with basic EPS of ₹-0.06 (consolidated, parsed from the company's exchange filing).
Tarsons Products Limited reported revenue of ₹124 Cr in Q2 FY27, up 20.8% from ₹102 Cr in Q2 FY26 and up 12.2% from ₹110 Cr in Q1 FY27.
Promoters held 47.30% of Tarsons Products Limited's shares as of Sept 2026, against 47.31% in Sept 2025 (−0.01 percentage points).
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.